Bulletin Contents
Home Page
Medexus Pharmaceuticals Inc. 
Listed Company 

BULLETIN TYPE: Normal Course Issuer Bid
BULLETIN DATE: May 13, 2019
TSX Venture Tier 2 Company

TSX Venture Exchange has been advised by the Company that pursuant to a Notice of Intention to make a Normal Course Issuer Bid dated May 13, 2019, it may repurchase for cancellation, up to 1,005,333 shares in its own capital stock. The purchases are to be made through the facilities of TSX Venture Exchange or other recognized marketplaces during the period May 16, 2019 to May 15, 2020. Purchases pursuant to the bid will be made by Canaccord Genuity Corp. (Len Sauer) on behalf of the Company.